Rejected

An erratum was issued for: Myocardial Infarction by Percutaneous Embolization Coil Deployment in a Swine Model. The Protocol and Discussion sections were updated. Step 3.5 was updated from: Clean the right femoral area with surgical soap and antiseptic povidone-iodine solution under sterile conditions to: Clean the right femoral area with surgical soap followed by alternating antiseptic povidone-iodine solution and alcohol 3 times under sterile conditions. Section 9 was updated from: 9. Euthanasia method Under previous sedation and anesthesia, as previously described, administer an IV sodium thiopental overdose (200 mg/kg). Confirm cardiorespiratory arrest and death by monitoring vital signs (electrocardiogram, blood pressure, capnography). to: 9. Postoperative pain assessment and monitoring During the post-surgical follow-up, monitor the general condition of the animals, including the respiratory rate, food and water intake, activity and interaction with the other individuals, appearance and coloration of the skin, and the evolution of the surgical wound. Apply a daily supervision protocol according to the following scoring criteria: – Weight: 0: Normal 1: <10% weight loss 2: 10-20% weight loss 3:> 20% weight loss – Body condition: 0: Good: non-prominent vertebrae, pelvic or spinal bones 2: Regular: evidence of spinal segmentation, palpable pelvic bones 3: Emaciation: extremely marked skeleton, little or no meat to cover – Behavior: 0: Normal: Active and interactive in your environment 1: Slight decline in activity and less interactive 2: Abnormal: pronounced decline in activity, isolated 3: Abnormal: Immobile or hyperactivity, possible self-harm – Physical appearance: 0: Normal: skin/hair shiny and eyes bright 1: Disappears embalming, skin/hair without shine 2: Poor skin/nasal secretions 3: Poor skin, abnormal or hunched posture – Behavioral disorders: 0: None 1: Inability to move normally 2: Unable to reach food/drink, isolated from other animals 3: Intention to hide/corner, does not respond to stimuli (dying) – Clinical signs: 0: None 1: Hypothermia, fever, mild respiratory failure 2: Infection of the surgical wound, moderate respiratory failure with muco-bloody secretions 3: Heart failure, severe respiratory failure (cyanosis, open mouth) Score: – 1-5: Supervise the animals once a day. – 6-12: Provide supportive therapy if necessary. – Any animal with a score of 3 in any of the above parameters or with a total score >12 will be euthanized. NOTE: The animals should be monitored daily by the animal care staff and twice a week by the research and veterinary team. Although no pain and distress are expected from the procedure, if any animal shows signs of pain, give analgesic therapy (tramadol, oral, 2-4 mg/kg, daily). If any animal does not respond to analgesic medication and shows signs of chronic pain (very low probability), euthanize the animal with an anesthetic overdose (sodium thiopental, IV, 200 mg/kg). If the surgical wound shows signs of infection (low probability) despite the antibiotic therapy administered, treat the wound daily and initiate a new antibiotic regimen (cefquinome sulphate, IM, 2 mg/kg, daily). 10. Euthanasia method Under previous sedation and anesthesia, as previously described, administer an IV sodium thiopental overdose (200 mg/kg). Confirm cardiorespiratory arrest and death by monitoring vital signs (electrocardiogram, blood pressure, capnography).

The knowledge of the COVID-19 symptomatology has increased since the beginning of the SARS-CoV-2 pandemic. The symptoms of nervous system involvement have been observed across the spectrum of COVID-19 severity. Reports describing difficulties of nerve roots are rare; the affection of brain and spinal cord by SARS-CoV-2 is of leading interest. Our aim therefore is to describe the radicular pain deterioration in the group of nine chronic lumbosacral radicular syndrome sufferers in acute COVID-19. The intensity of radicular pain was evaluated by the Visual Analogue Scale (VAS). The VAS score in acute infection increased from 5.6 ± 1.1 to 8.0 ± 1.3 (Cohen's = 1.99) over the course of COVID-19, indicating dramatic aggravation of pain intensity. However, the VAS score decreased spontaneously to pre-infection levels after 4 weeks of COVID-19 recovery (5.8 ± 1.1). The acute SARS-CoV-2 infection worsened the pre-existing neural root irritation symptomatology, which may be ascribed to SARS-CoV-2 radiculitis of neural roots already compressed by the previous disc herniation. These findings based on clinical observations indicate that the neurotropism of novel coronavirus infection can play an important role in the neural root irritation symptomatology deterioration in patients with chronic pre-existing lumbosacral radicular syndrome.

Atopic dermatitis is a skin disorder caused by skin dryness and barrier dysfunction, resulting in skin inflammation and chronic itch (or pruritus). The pathogenesis of atopic dermatitis is thought to be initiated by a lowering of the itch threshold due to dry skin. This lowering of the itch threshold is at least partially due to the increase in intraepidermal nerve fibers and sensitization of sensory nerves by interleukin (IL)-33 produced and secreted by keratinocytes. Such skin is easily prone to itch due to mechanical stimuli, such as rubbing of clothing and chemical stimuli from itch mediators. In patients with atopic dermatitis, once itch occurs, further itch is induced by scratching, and the associated scratching breaks down the skin barrier. Disruption of the skin barrier allows entry into the epidermis of external foreign substances, such as allergens derived from house dust mites, leading to an increased induction of type 2 inflammatory responses. As a result, type 2 cytokines IL-4, IL-13, and IL-31 are mainly secreted by Th2 cells, and their action on sensory nerve fibers causes further itch sensitization. These sequences of events are thought to occur simultaneously in patients with atopic dermatitis, leading to a vicious itch-scratch cycle. This vicious cycle becomes a negative spiral that leads to disease burden. Therefore, controlling itch is essential for the treatment of atopic dermatitis. In this review, we summarize and discuss advances in the mechanisms of peripheral itch sensitization in atopic dermatitis, focusing on skin barrier-neuro-immune triadic connectivity.

A spinal cord injury (SCI) is a devastating, life-changing event that has profoundly deleterious effects on an individual's health and well-being. Dysregulation of neuromuscular, cardiometabolic, and endocrine organ systems following an SCI contribute to excess morbidity, mortality and a poor quality of life. As no effective treatments currently exist for SCI, the development of novel strategies to improve the functional and health status of individuals living with SCI are much needed. To address this knowledge gap, the current study will determine whether a Home-Based Multimodality Functional Recovery and Metabolic Health Enhancement Program that consists of functional electrical stimulation of the lower extremity during leg cycling (FES-LC) plus arm ergometry (AE) administered using behavioral motivational strategies, and testosterone therapy, is more efficacious than FES-LC plus AE and placebo in improving aerobic capacity, musculoskeletal health, function, metabolism, and wellbeing in SCI.

A major cause of morbidity in lower limb amputees is phantom limb pain (PLP) and residual limb pain (RLP). This study aimed to determine whether a variation of the surgical technique of inserting nerve endings into adjacent muscle bellies at the time of lower limb amputation can decrease the incidence and severity of PLP and RLP.

Posterior reversible encephalopathy syndrome (PRES) is a clinico-radiological syndrome characterized by a neurotoxic state with vasogenic edema. We studied the clinical profile, predisposing factors, imaging features, and outcome of PRES in children receiving treatment for hematolymphoid malignancies.

Multiple studies have utilized social media to evaluate patient-perceived outcomes after surgery. To the authors knowledge, no published studies have evaluated patient-perceived outcomes after ACDF surgery through social media analysis.

The increasing morbidness of brain disorders and conditions such as anxiety, stress, depression, Alzheimer's disease, Parkinson's disease, and others have become severe. Although researchers have spent a significant amount of time examining these diseases and providing many benefits, there are still limited drugs available to treat these disorders. Eugenol, a dietary component present in numerous plants and herbs, possesses various health benefits. In various preclinical studies, eugenol has provided significant protective effects against a variety of brain disorders. Thus, including eugenol in the diet can fight various diseases and ensure a healthy life. Considering the fruitful impact of this compound, this review focuses on the brain disorders in which eugenol was used and summarizes the beneficial properties of eugenol and its role in treating various brain diseases.

There is a long history of informal use of Cannabis sativa (commonly called cannabis) for many purposes, including treating various ailments worldwide. However, the legalization of cannabis in multiple countries, specifically for medical purposes, has grabbed the researchers' attention to discover the scientific evidence of cannabis's beneficial effects. Among over 500 identified compounds (cannabinoids), Δ9-Tetrahydrocannabinol (THC) and cannabidiol (CBD) are two major active cannabinoids derived from cannabis. Cannabinoids exert their effects through cannabinoid receptors (CB1R and CB2R). In the recent past, clinical trials have shown the efficacy of cannabis and cannabinoids for various human ailments such as cancer, neurological disorders, inflammatory bowel disease, chronic pain, and metabolic disorders. The commonly used constituents and derivatives of cannabis include CBD, THC, THCV, dronabinol, nabilone, and nabiximol. The cannabis constituents have also been used in combination with other agents such as megestrol acetate in some clinical trials. The common routes for the administration of cannabis are oral, sublingual, or topical. Cannabis has also been consumed through smoking, inhalation, or with food and tea. As high as 572 patients and as low as nine patients have participated in a single clinical trial. Cannabis is legalized in some countries with restrictions, such as Belize, Canada, Colombia, Costa Rica, The Czech Republic, Jamaica, Netherlands, South Africa, Spain, and Uruguay. This article provides a compilation of published studies focusing on clinal trials on the therapeutic effects of cannabis. The adverse effects of cannabis and its constituents are also discussed.

Administration of opioids to suppress pain plays a major role in modern anesthesia. Measuring depth of hypnosis and neuromuscular recovery are already well established, and devices for pain monitoring are available. Nonetheless pain monitoring is rare in clinical practice. Recently, the pain monitoring device PMD200 (Medasense Biometrics™ , Israel) was introduced. It non-invasively measures heart rate, heart rate variability, skin resistance, resistance variability, temperature and movement to calculate a nociception level (NoL) index. The NoL index range starts at zero, which is equivalent to being painless, and goes up to a value of 100. The validity and reliability of NoL monitoring is the content of current studies.